



SHAREABLE PDF

# Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline

Charles L. Daley<sup>1,2,26</sup>, Jonathan M. Iaccarino<sup>3</sup>, Christoph Lange<sup>4,5,6,7,26</sup>, Emmanuelle Cambau<sup>8,26</sup>, Richard J. Wallace Jr<sup>9,26</sup>, Claire Andrejak<sup>10,11</sup>, Erik C. Böttger<sup>12</sup>, Jan Brozek<sup>13</sup>, David E. Griffith<sup>14</sup>, Lorenzo Guglielmetti<sup>15</sup>, Gwen A. Huitt<sup>1,2</sup>, Shandra L. Knight<sup>16</sup>, Philip Leitman<sup>17</sup>, Theodore K. Marras<sup>18</sup>, Kenneth N. Olivier<sup>19</sup>, Miguel Santin<sup>20</sup>, Jason E. Stout<sup>21</sup>, Enrico Tortoli<sup>22</sup>, Jakko van Ingen<sup>23</sup>, Dirk Wagner<sup>24</sup> and Kevin L. Winthrop<sup>25</sup>

**Affiliations:** <sup>1</sup>Dept of Medicine, National Jewish Health, Denver, CO, USA. <sup>2</sup>Dept of Medicine, University of Colorado School of Medicine, Aurora, CO, USA. <sup>3</sup>Pulmonary Center, Boston University School of Medicine, Boston, MA, USA. <sup>4</sup>Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany. <sup>5</sup>German Center for Infection Research (DZIF), Clinical Tuberculosis Unit, Borstel, Germany. <sup>6</sup>Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany. <sup>7</sup>Dept of Medicine, Karolinska Institute, Stockholm, Sweden. <sup>8</sup>National Reference Center for Mycobacteria and Antimycobacterial Resistance, APHP -Hôpital Lariboisière, Bacteriology; Inserm, University Paris Diderot, IAME UMR1137, Paris, France. <sup>9</sup>Mycobacteria/Nocardia Laboratory, Dept of Microbiology, The University of Texas Health Science Center, Tyler, TX, USA. <sup>10</sup>Respiratory and Intensive Care Unit, University Hospital Amiens, Amiens, France. <sup>11</sup>EA 4294, AGIR, Jules Verne Picardy University, Amiens, France. <sup>12</sup>Institute of Medical Microbiology, National Reference Center for Mycobacteria, University of Zurich, Zurich, Switzerland. <sup>13</sup>Dept of Clinical Epidemiology and Biostatistics, McMaster University Health Sciences Centre, Hamilton, ON, Canada. <sup>14</sup>Pulmonary Infectious Disease Section, University of Texas Health Science Center, Tyler, TX, USA. <sup>15</sup>Team E13 (Bactériologie), Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche 7, INSERM, IAME UMR1137, Paris, France. <sup>16</sup>Library and Knowledge Services, National Jewish Health, Denver, CO, USA. <sup>17</sup>NTM Info and Research, Miami, FL, USA. <sup>18</sup>Dept of Medicine, University of Toronto and University Health Network, Toronto, ON, Canada. <sup>19</sup>Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, MD, USA. <sup>20</sup>Service of Infectious Diseases, Bellvitge University Hospital-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain. <sup>21</sup>Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC, USA. <sup>22</sup>Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. <sup>23</sup>Radboud Center for Infectious Diseases, Dept of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands. <sup>24</sup>Division of Infectious Diseases, Dept of Medicine II, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. <sup>25</sup>Divisions of Infectious Diseases, Schools of Public Health and Medicine, Oregon Health and Science University, Portland, OR, USA. <sup>26</sup>C.L. Daley, C. Lange, E. Cambau and R.J. Wallace Jr are coauthors of this guideline committee.

**Correspondence:** Charles L. Daley, National Jewish Health, 1400 Jackson St, Denver, CO 80206, USA. E-mail: daleyc@njhealth.org



@ERSpublications

The official ATS/ERS/ESCMID/IDSA clinical practice guidelines provide 31 evidence-based recommendations for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease <https://bit.ly/3fOEwlc>

**Cite this article as:** Daley CL, Iaccarino JM, Lange C, *et al.* Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. *Eur Respir J* 2020; 56: 2000535 [<https://doi.org/10.1183/13993003.00535-2020>].

Copyright © The Author(s) 2020. This version published by the European Respiratory Society in the *European Respiratory Journal*, and jointly with *Clinical Infectious Diseases*. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article.

This single-page version can be shared freely online.

**ABSTRACT** Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as *Mycobacterium avium* complex, *Mycobacterium kansasii*, and *Mycobacterium xenopi* among the slowly growing NTM and *Mycobacterium abscessus* among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.